Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Incidence and Risk of Cardiac Events in Patients With Previously Treated Multiple Myeloma Versus Matched Patients Without Multiple Myeloma: An Observational, Retrospective, Cohort Study.

Kistler KD, Kalman J, Sahni G, Murphy B, Werther W, Rajangam K, Chari A.

Clin Lymphoma Myeloma Leuk. 2017 Feb;17(2):89-96.e3. doi: 10.1016/j.clml.2016.11.009. Epub 2016 Nov 22.

2.

Population Pharmacokinetics and Exposure-Response Relationship of Carfilzomib in Patients With Multiple Myeloma.

Ou Y, Doshi S, Nguyen A, Jonsson F, Aggarwal S, Rajangam K, Dimopoulos MA, Stewart AK, Badros A, Papadopoulos KP, Siegel D, Jagannath S, Vij R, Niesvizky R, Graham R, Visich J.

J Clin Pharmacol. 2017 May;57(5):663-677. doi: 10.1002/jcph.850. Epub 2016 Dec 7.

PMID:
27925676
3.

A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS).

Hájek R, Masszi T, Petrucci MT, Palumbo A, Rosiñol L, Nagler A, Yong KL, Oriol A, Minarik J, Pour L, Dimopoulos MA, Maisnar V, Rossi D, Kasparu H, Van Droogenbroeck J, Yehuda DB, Hardan I, Jenner M, Calbecka M, Dávid M, de la Rubia J, Drach J, Gasztonyi Z, Górnik S, Leleu X, Munder M, Offidani M, Zojer N, Rajangam K, Chang YL, San-Miguel JF, Ludwig H.

Leukemia. 2017 Jan;31(1):107-114. doi: 10.1038/leu.2016.176. Epub 2016 Jun 24.

4.

Relationship Between Carfilzomib Dose and Efficacy Outcomes in Patients With Relapsed and/or Refractory Multiple Myeloma.

Squifflet P, Michiels S, Siegel D, Vij R, Jagannath S, Saad ED, Rajangam K, Ro SK, Buyse M.

Clin Lymphoma Myeloma Leuk. 2015 Nov;15(11):680-6. doi: 10.1016/j.clml.2015.09.005. Epub 2015 Sep 25.

PMID:
26482107
5.

Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies.

Siegel D, Martin T, Nooka A, Harvey RD, Vij R, Niesvizky R, Badros AZ, Jagannath S, McCulloch L, Rajangam K, Lonial S.

Haematologica. 2013 Nov;98(11):1753-61. doi: 10.3324/haematol.2013.089334. Epub 2013 Aug 9.

6.

Capturing the stem cell paracrine effect using heparin-presenting nanofibres to treat cardiovascular diseases.

Webber MJ, Han X, Murthy SN, Rajangam K, Stupp SI, Lomasney JW.

J Tissue Eng Regen Med. 2010 Dec;4(8):600-10. doi: 10.1002/term.273.

7.

Peptide amphiphile nanostructure-heparin interactions and their relationship to bioactivity.

Rajangam K, Arnold MS, Rocco MA, Stupp SI.

Biomaterials. 2008 Aug;29(23):3298-305. doi: 10.1016/j.biomaterials.2008.04.008. Epub 2008 May 12.

8.

Modulation of fluorescence through coassembly of molecules in organic nanostructures.

Behanna HA, Rajangam K, Stupp SI.

J Am Chem Soc. 2007 Jan 17;129(2):321-7.

PMID:
17212411
9.

Heparin binding nanostructures to promote growth of blood vessels.

Rajangam K, Behanna HA, Hui MJ, Han X, Hulvat JF, Lomasney JW, Stupp SI.

Nano Lett. 2006 Sep;6(9):2086-90.

PMID:
16968030
10.

Partial nephrectomy in cystic partially differentiated nephroblastoma.

Rajangam K, Narasimhan KL, Trehan A, Rawal A, Radotra B, Rao KL.

J Pediatr Surg. 2000 Mar;35(3):510-2.

PMID:
10726701
11.

Frequency of cervical spine involvement in rheumatoid arthritis.

Rajangam K, Thomas IM.

J Indian Med Assoc. 1995 Apr;93(4):138-9, 137.

PMID:
8699039

Supplemental Content

Loading ...
Support Center